Grass pollen sublingual immunotherapy for seasonal rhinoconjunctivitis: a randomized controlled trial

Summary Background Previous studies suggest that sublingual immunotherapy (SLIT) represents a safer alternative to injection immunotherapy but equivalent efficacy is yet to be confirmed. Objective To evaluate the efficacy and safety of SLIT in grass pollen‐induced seasonal rhinoconjunctivitis. Metho...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental allergy 2002-04, Vol.32 (4), p.507-514
Main Authors: Lima, M. Torres, Wilson, D., Pitkin, L., Roberts, A., Nouri-Aria, K., Jacobson, M., Walker, S., Durham, S.
Format: Article
Language:English
Subjects:
Administration, Sublingual
Adult
Allergens - therapeutic use
antibodies
Antigens, CD1 - analysis
Antigens, CD1 - immunology
Biological and medical sciences
CD3 Complex - analysis
CD3 Complex - immunology
Conjunctivitis, Allergic - diagnosis
Conjunctivitis, Allergic - immunology
Conjunctivitis, Allergic - therapy
cytokines
Double-Blind Method
Female
hayfever
Humans
Immunoglobulin E - blood
Immunoglobulin G - blood
Immunohistochemistry
Immunopathology
immunotherapy
Immunotherapy (general aspects)
Interleukin-12 - biosynthesis
Interleukin-12 - genetics
Male
Medical sciences
Middle Aged
Mouth Mucosa - cytology
Mouth Mucosa - metabolism
Poaceae - immunology
Pollen - immunology
Rhinitis, Allergic, Seasonal - diagnosis
Rhinitis, Allergic, Seasonal - immunology
Rhinitis, Allergic, Seasonal - therapy
rhinoconjunctivitis
RNA, Messenger - biosynthesis
sublingual
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Previous studies suggest that sublingual immunotherapy (SLIT) represents a safer alternative to injection immunotherapy but equivalent efficacy is yet to be confirmed. Objective To evaluate the efficacy and safety of SLIT in grass pollen‐induced seasonal rhinoconjunctivitis. Methods A randomized, placebo‐controlled trial in 56 adults over 18 months. Outcome measures included diary scores of seasonal symptoms and medication use, overall assessments, conjunctival and intradermal provocation tests and serum antibody measurements. To investigate possible mechanisms, sublingual biopsies were taken for measurement of local T cells, antigen‐presenting cells and IL‐12 mRNA expression. Results There were no significant differences between the immunotherapy (IT) and placebo groups for diary symptom scores (P = 0.48) or rescue medication (P = 0.19). The patients' overall assessment of hayfever severity compared with previous years showed a highly significant improvement in favour of the IT group (P 
ISSN:0954-7894
1365-2222
DOI:10.1046/j.0954-7894.2002.01327.x